Buprenorphine

Buprenorphine, semisynthetic opioid medication used primarily to treat opioid use disorder (OUD) and to manage severe chronic pain. Buprenorphine is especially useful for reducing opioid withdrawal and craving while providing some protection against the effects of more powerful opioid substances. As an analgesic (pain-reliever), buprenorphine reduces pain by activating opioid receptors involved in pain signaling. Its prolonged action makes it particularly suited to certain forms of persistent pain, with specialized formulations designed to provide sustained relief.

History and discovery

Buprenorphine is derived from thebaine, an alkaloid that occurs naturally in the opium poppy (Papaver somniferum). It was initially synthesized in 1966 by researchers at the British pharmaceutical company Reckitt & Colman (later Reckitt Benckiser) as one of a series of compounds investigated in the search for an opioid analgesic that could provide effective pain relief while presenting fewer risks than drugs such as morphine. Hence, the drug was initially developed as an analgesic, entering clinical use in the late 1970s.

The following decade, buprenorphine emerged as a promising drug for the treatment of opioid dependence. Research showed that it could reduce withdrawal symptoms and opioid use while allowing patients to function without the cycles of intoxication and withdrawal associated with shorter-acting opioids. In 2002 the U.S. Food and Drug Administration (FDA) approved buprenorphine formulations for treating opioid dependence, now generally referred to as OUD. An important feature of the new treatment was that qualified physicians could prescribe it in office-based settings rather than requiring patients to obtain medication exclusively through specialized opioid-treatment programs. Subsequent regulatory changes further expanded access to buprenorphine treatment.

Discover how ordinary objects work, and expand your understanding of the familiar.

SIGN UP

" height="20" alt="HEW Logo">

Thank you for signing up!"

Back to homepage

By clicking "Sign Up", you consent to the Britannica Privacy Policy and Terms of Use.

Mechanism of action

Buprenorphine produces its main therapeutic and physiological effects by binding to mu (μ) opioid receptors. These receptors normally respond to endorphins, which are naturally occurring signaling molecules, and are activated by opioid drugs. Heroin, morphine, fentanyl, and certain other opioids are full agonists at mu receptors—after binding, they strongly activate the receptors. Buprenorphine has very high affinity for the same receptors, meaning that it binds to them tightly, but it has lower intrinsic activity. It therefore behaves as a partial agonist (mildly activating mu receptors).

This combination—strong binding but limited activation—is central to the clinical utility of buprenorphine. In a person who has developed opioid dependence, the drug can activate enough mu receptors to suppress withdrawal symptoms and reduce cravings. At the same time, increasing the dose beyond a certain range produces progressively smaller increases in some opioid effects. This phenomenon is known as a ceiling effect and is especially important in limiting adverse effects, particularly respiratory depression.

Because buprenorphine binds strongly to mu receptors, it can also prevent or reduce the effects of other opioids that attempt to bind to the same receptors. This high affinity creates an important complication; however, if buprenorphine is given too soon after a person has used certain full opioid agonists, it can displace the full agonist from receptors while providing less receptor activation itself. The sudden decrease in opioid activity can cause precipitated withdrawal, characterized by an abrupt onset of withdrawal symptoms.

Buprenorphine also interacts with other opioid receptors, including kappa (κ) receptors, at which it serves principally as an antagonist. Its overall pharmacology is therefore more complex than that of many conventional opioid drugs.

Explore Britannica Premium!

The trusted destination for professionals, college students, and lifelong learners.

SUBSCRIBE

Medical uses

Buprenorphine’s principal use is in the treatment of OUD, a chronic condition characterized by problematic opioid use despite harmful consequences. The drug is one of several medications, along with methadone and naltrexone, used for this purpose. To treat OUD, buprenorphine may be administered alone or together with naloxone. In combination products naloxone is included primarily to discourage certain forms of misuse. For example, when the medication is taken as directed, under the tongue or inside the cheek, relatively little naloxone reaches the bloodstream. However, if a person tries to inject the drug, naloxone blocks buprenorphine’s opioid effects, triggering withdrawal in a person with opioid dependence.

Buprenorphine is also used as an analgesic. Formulations intended for pain treatment include injections and transdermal patches that release the drug gradually through the skin.

Side effects and risks

Buprenorphine use is linked to various adverse effects, ranging from mild to potentially life-threatening. Mild effects, such as drowsiness, headache, insomnia, nausea, and vomiting, are common. Although buprenorphine can reduce the risk of respiratory depression, in rare instances it may severely depress breathing, to the point of being life-threatening. This risk is increased markedly when buprenorphine is combined with other substances that depress the central nervous system, particularly alcohol, benzodiazepines, and certain sedating medications. Other possible complications include liver disease, allergic reactions, low blood pressure, and, when abruptly discontinued, withdrawal symptoms. The potential for misuse and physical dependence impacts the severity of adverse effects linked to buprenorphine.